Cite
MLA Citation
Neeraj Gupta et al.. “Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study.” CPT: pharmacometrics & systems pharmacology, vol. 9, 2020, pp. 718–730. http://access.bl.uk/ark:/81055/vdc_100118051903.0x00000b